Capital Insight Partners LLC Purchases Shares of 14,000 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Capital Insight Partners LLC acquired a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 14,000 shares of the company’s stock, valued at approximately $252,000.

Other hedge funds also recently modified their holdings of the company. Greenlight Capital Inc. purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth $2,803,000. Glenview Capital Management LLC bought a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $16,752,000. Burford Brothers Inc. bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $1,458,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $7,099,000. Finally, Quadrature Capital Ltd bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $203,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the sale, the insider now owns 45,060 shares in the company, valued at approximately $777,285. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.55% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on TEVA shares. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 3rd. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group raised their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Barclays increased their price objective on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Finally, Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $18.89.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $17.41 on Friday. Teva Pharmaceutical Industries Limited has a 52-week low of $8.06 and a 52-week high of $19.08. The business’s fifty day moving average is $17.87 and its 200 day moving average is $16.46. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.